Q2 2026 · Form 13F Ledger數據來源:SEC EDGAR  
H

HOLDER.TOP

誰持有什麼——美股機構持倉的季度賬本。
EN · 简 · 繁
機構 / Opaleye Management Inc.
Form 13F · Q2 2026

Opaleye Management Inc.

CIK 1595855申報日 2026-08-1413F-HR 在 EDGAR 查看原始申報 ↗
$11.0亿
申報組合市值
58
持倉數量
12
Quarters on record
Top 50
持倉數量

Opaleye Management Inc.——持倉

共 58 個持倉中的前 50 名,按申報市值排名。股數變動與上一季度對比。
#證券股數股數環比市值佔其組合
1LQDA Liquidia Corporation2.4M−3.8%$2.0亿17.7%
2ETON Eton Pharmaceuticals Inc2.9M+0.0%$1.0亿9.4%
3HROW Harrow Inc2.4M−15.3%$1.0亿9.2%
4IRON Disc Medicine Inc855,000+103.1%$6253万5.7%
5URGN Urogen Pharma Ltd1.4M+0.7%$5299万4.8%
6APOGEE THERAPEUTICS INC Apogee Therapeutics Inc390,000+0.0%$5176万4.7%
7MGTX Meiragtx Hldgs Plc3.5M+67.2%$4796万4.3%
8SLGL Sol-Gel Technologies Ltd500,000+0.0%$3707万3.4%
9RZLT Rezolute Inc6.3M+0.0%$3276万3.0%
10TGTX Tg Therapeutics Inc535,000+0.0%$2939万2.7%
11IMMX Immix Biopharma Inc2.3M—$2418万2.2%
12CBIO Crescent Biopharma Inc.1.3M+0.5%$2375万2.2%
13STOK Stoke Therapeutics Inc700,000+0.0%$2290万2.1%
14ACOG Alpha Cognition Inc2.9M+13.0%$2091万1.9%
15EWTX Edgewise Therapeutics Inc500,000+0.0%$2032万1.8%
16RVMD Revolution Medicines Inc100,000+0.0%$1873万1.7%
17GLUE Monte Rosa Therapeutics Inc745,000—$1803万1.6%
18ALMS Alumis Inc550,000+0.0%$1548万1.4%
19CDXS Codexis Inc6.8M+0.0%$1533万1.4%
20REPL Replimune Group Inc1.4M—$1533万1.4%
21XOMA ROYALTY CORPORATION Xoma Royalty Corporation338,374+12.8%$1438万1.3%
22MBX Mbx Biosciences Inc260,000+0.0%$1435万1.3%
23RYTM Rhythm Pharmaceuticals Inc122,500−0.4%$1360万1.2%
24EDIT Editas Medicine Inc3.9M+100.4%$1251万1.1%
25PTGX Protagonist Therapeutics Inc100,000+0.0%$1226万1.1%
26CABA Cabaletta Bio Inc3.9M+180.0%$1202万1.1%
27QTTB Q32 Bio Inc931,000−25.9%$1186万1.1%
28ANNX Annexon Inc1.7M−26.5%$979万0.9%
29VSTM Verastem Inc1.8M—$688万0.6%
30ZNTL Zentalis Pharmaceuticals Inc1.4M+0.0%$685万0.6%
31RLMD Relmada Therapeutics Inc935,000+0.0%$647万0.6%
32OCUL Ocular Therapeutix Inc600,000+0.0%$589万0.5%
33TRVI Trevi Therapeutics Inc310,000−10.2%$578万0.5%
34BBOT Bridgebio Oncology Therapeut700,000+1213.8%$533万0.5%
35LYEL Lyell Immunopharma Inc344,025+334.9%$483万0.4%
36IRD Opus Genetics Inc1.1M+0.4%$462万0.4%
37FDMT 4D Molecular Therapeutics In334,437+197.8%$445万0.4%
38NTLA Intellia Therapeutics Inc250,000+2.0%$423万0.4%
39VYGR Voyager Therapeutics Inc1.2M+3.0%$415万0.4%
40BDSX Biodesix Inc180,000−24.4%$406万0.4%
41RCKT Rocket Pharmaceuticals Inc1.0M+4.7%$342万0.3%
42JBIO Jade Biosciences Inc145,000−66.1%$322万0.3%
43SNWV Sanuwave Health Inc306,140−68.8%$306万0.3%
44FBIO Fortress Biotech Inc890,000−14.6%$272万0.2%
45DERM Journey Med Corp350,000−63.5%$248万0.2%
46PHAT Phathom Pharmaceuticals Inc185,589—$201万0.2%
47INBX Inhibrx Biosciences Inc20,291—$192万0.2%
48ENTA Enanta Pharmaceuticals Inc125,000+0.0%$182万0.2%
49COAG Hemab Therapeutics Hldgs Inc47,652—$175万0.2%
50TRAX First Tracks Biotherapeutics65,000—$131万0.1%
來源:經 SEC EDGAR 的 Form 13F 申報。持倉截至 2026 年 6 月 30 日。期權(看漲/看跌)不計入股數。